Evidence map›Paper›PMID 32203580›Full record

ArticleBrain : a journal of neurology2020

Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration.

Sara Fernández-Cabello, Martin Kronbichler, Koene R A Van Dijk, James A Goodman, R Nathan Spreng, Taylor W Schmitz, Alzheimer’s Disease Neuroimaging Initiative

Open access · greenAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 165 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Measuring in-vivo tau pathology in the basal forebrain with PET imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Reduction in hippocampal cholinergic neurostimulating peptide enhances memory impairment in AppAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  9. A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  10. Article
  11. Article
  12. The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  14. Probabilistic mapping and automated segmentation of human brainstem white matter bundles.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Sara Fernández-CabelloDepartment of Psychology, University of Salzburg, Salzburg, Austria.
Martin KronbichlerDepartment of Psychology, University of Salzburg, Salzburg, Austria.
Koene R A Van DijkClinical and Translational Imaging, Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
James A GoodmanClinical and Translational Imaging, Early Clinical Development, Pfizer Inc, Cambridge, MA, USA.
R Nathan SprengLaboratory of Brain and Cognition, Montreal Neurological Institute, Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
Taylor W SchmitzBrain and Mind Institute, Western University, London, ON, Canada.
Alzheimer’s Disease Neuroimaging Initiative
Pfizer (United States) · USUniversity of Salzburg · ATMontreal Neurological Institute and Hospital · CAWestern University · CA

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
In vivo staging of preclinical Alzheimer's disease progressionR03AG060263 · NIA · MCGILL UNIVERSITY · PI SPRENG, ROBERT NATHAN · 2018 to 2019
$106k
Austrian Science Fund FWF W 1233NIA NIH HHS R03 AG060263NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Alzheimer's disease neurodegeneration is thought to spread across anatomically and functionally connected brain regions. However, the precise sequence of spread remains ambiguous. The prevailing model used to guide in vivo human neuroimaging and non-human animal research assumes that Alzheimer's degeneration starts in the entorhinal cortices, before spreading to the temporoparietal cortex. Challenging this model, we previously provided evidence that in vivo markers of neurodegeneration within the nucleus basalis of Meynert (NbM), a subregion of the basal forebrain heavily populated by cortically projecting cholinergic neurons, precedes and predicts entorhinal degeneration. There have been few systematic attempts at directly comparing staging models using in vivo longitudinal biomarker data, and none to our knowledge testing if comparative evidence generalizes across independent samples. Here we addressed the sequence of pathological staging in Alzheimer's disease using two independent samples of the Alzheimer's Disease Neuroimaging Initiative (n1 = 284; n2 = 553) with harmonized CSF assays of amyloid-β and hyperphosphorylated tau (pTau), and longitudinal structural MRI data over 2 years. We derived measures of grey matter degeneration in a priori NbM and the entorhinal cortical regions of interest. To examine the spreading of degeneration, we used a predictive modelling strategy that tests whether baseline grey matter volume in a seed region accounts for longitudinal change in a target region. We demonstrated that predictive spread favoured the NbM→entorhinal over the entorhinal→NbM model. This evidence generalized across the independent samples. We also showed that CSF concentrations of pTau/amyloid-β moderated the observed predictive relationship, consistent with evidence in rodent models of an underlying trans-synaptic mechanism of pathophysiological spread. The moderating effect of CSF was robust to additional factors, including clinical diagnosis. We then applied our predictive modelling strategy to an exploratory whole-brain voxel-wise analysis to examine the spatial specificity of the NbM→entorhinal model. We found that smaller baseline NbM volumes predicted greater degeneration in localized regions of the entorhinal and perirhinal cortices. By contrast, smaller baseline entorhinal volumes predicted degeneration in the medial temporal cortex, recapitulating a prior influential staging model. Our findings suggest that degeneration of the basal forebrain cholinergic projection system is a robust and reliable upstream event of entorhinal and neocortical degeneration, calling into question a prevailing view of Alzheimer's disease pathogenesis.

Indexed as

Disease ProgressionAgedAlzheimer DiseaseAmyloid beta-PeptidesBasal ForebrainBasal Nucleus of MeynertBiomarkersDatabases, FactualEntorhinal CortexFemaleGray MatterHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNerve DegenerationAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseasebasal forebrainentorhinal cortexNbMnucleus basalis of Meynert

Identifiers

PMID32203580
PMCPMC7092749
OpenAlexW3012926572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.